美国 · SEC FORM 4
Disc Medicine, Inc.
IRON · Nasdaq · CIK 0001816736 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
59 同一窗口内观察到的 Form 4 交易行
39 sales · 20 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2024-06-17 · Bitterman Kevin · $8.0M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Yu Jonathan Yen-WenChief Operating Officer
○▼○▼○▼○▼○▼○▼
Quisel John DChief Executive Officer
○▼○▼○▼○
Bitterman KevinDirector
▼▼▼▼○▼
Khara RahulChief Legal Officer
○▼○▼○▼
● 买入▼ 卖出○ 其他
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-06-17 · Bitterman Kevin.
近期 Form 4 活动
0买入
92卖出
35其他 Form 4 交易行
42SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出39 sale line(s) · 仅供背景
其他20 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 7,270,420
- 上期报告
- 7,207,702
- 日均成交量
- 568,317
- 回补天数
- 12.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-06-17 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Capital GP VIII LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 83,334 | USD 36.00 | USD 3,000,024 | SEC 申报 ↗ |
| 2024-06-17 | Bitterman Kevin | 买入 (P) | Common Stock | 222,223 | USD 36.00 | USD 8,000,028 | SEC 申报 ↗ |
| 2024-06-17 | Ashiya Mona | 买入 (P) | Common Stock | 83,334 | USD 36.00 | USD 3,000,024 | SEC 申报 ↗ |
| 2023-02-15 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VI LLC; OrbiMed Capital GP VIII LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 108,696 | USD 23.00 | USD 2,500,008 | SEC 申报 ↗ |
| 2023-02-15 | Ashiya Mona | 买入 (P) | Common Stock | 108,696 | USD 23.00 | USD 2,500,008 | SEC 申报 ↗ |
| 2023-02-15 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI DMI LLC; Access Industries Holdings LLC; Blavatnik Len | 买入 (P) | Common Stock | 434,783 | USD 23.00 | USD 10,000,009 | SEC 申报 ↗ |
| 2022-04-13 | Leonard Braden Michael | 买入 (P) | Common Stock | 191,769 | USD 1.52 | USD 291,489 | SEC 申报 ↗ |
| 2022-04-12 | Leonard Braden Michael | 买入 (P) | Common Stock | 258,744 | USD 1.41 | USD 364,666 | SEC 申报 ↗ |
| 2022-04-11 | Leonard Braden Michael | 买入 (P) | Common Stock | 504,487 | USD 1.35 | USD 681,057 | SEC 申报 ↗ |
| 2021-05-14 | Piekos Brian | 买入 (P) | Common Stock | 7,655 | USD 9.46 | USD 72,416 | SEC 申报 ↗ |
| 2021-05-14 | Meyenburg Jason Patrick | 买入 (P) | Common Stock | 13,000 | USD 9.46 | USD 122,980 | SEC 申报 ↗ |
| 2020-08-14 | FS Development Holdings, LLC; Foresite Capital Fund V, L.P.; Foresite Capital Management V, LLC; Tananbaum James B. | 买入 (P) | Class A Common Stock | 441,500 | USD 10.00 | USD 4,415,000 | SEC 申报 ↗ |
Form 4 申报证据
127 transaction lines in the latest 365-day window; 482 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Quisel John D | 期权行权／转换 (M) | Common Stock | 36,000 | USD 1.01 | USD 36,360 | SEC 申报 ↗ |
| 2026-09-11 | Bitterman Kevin | 卖出 (S) | Common Stock | 27,136 | USD 70.11 | USD 1,902,505 | SEC 申报 ↗ |
| 2026-09-11 | Bitterman Kevin | 期权行权／转换 (M) | Common Stock | 27,136 | USD 45.07 | USD 1,223,144 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Quisel John D | 期权行权／转换 (M) | Common Stock | 36,000 | USD 1.01 | USD 36,360 | SEC 申报 ↗ |
| 2026-09-11 | Bitterman Kevin | 卖出 (S) | Common Stock | 27,136 | USD 70.11 | USD 1,902,505 | SEC 申报 ↗ |
| 2026-09-11 | Bitterman Kevin | 期权行权／转换 (M) | Common Stock | 27,136 | USD 45.07 | USD 1,223,144 | SEC 申报 ↗ |
| 2026-09-04 | Bitterman Kevin | 卖出 (S) | Common Stock | 1,689 | USD 79.96 | USD 135,052 | SEC 申报 ↗ |
| 2026-09-03 | Bitterman Kevin | 卖出 (S) | Common Stock | 5,203 | USD 79.98 | USD 416,136 | SEC 申报 ↗ |
| 2026-09-02 | Bitterman Kevin | 卖出 (S) | Common Stock | 49,164 | USD 80.17 | USD 3,941,495 | SEC 申报 ↗ |
| 2026-09-01 | Bitterman Kevin | 卖出 (S) | Common Stock | 129 | USD 79.95 | USD 10,314 | SEC 申报 ↗ |
| 2026-08-25 | Yu Jonathan Yen-Wen | 卖出 (S) | Common Stock | 8,796 | USD 83.12 | USD 731,124 | SEC 申报 ↗ |
| 2026-08-25 | Yu Jonathan Yen-Wen | 期权行权／转换 (M) | Common Stock | 8,796 | USD 13.50 | USD 118,746 | SEC 申报 ↗ |
| 2026-08-24 | Yu Jonathan Yen-Wen | 卖出 (S) | Common Stock | 300 | USD 82.53 | USD 24,759 | SEC 申报 ↗ |
| 2026-08-24 | Yu Jonathan Yen-Wen | 期权行权／转换 (M) | Common Stock | 300 | USD 13.50 | USD 4,050 | SEC 申报 ↗ |
| 2026-08-17 | Quisel John D | 卖出 (S) | Common Stock | 33,000 | USD 79.15 | USD 2,612,052 | SEC 申报 ↗ |
| 2026-08-17 | Quisel John D | 期权行权／转换 (M) | Common Stock | 33,000 | USD 13.50 | USD 445,500 | SEC 申报 ↗ |
| 2026-08-12 | Yu Jonathan Yen-Wen | 卖出 (S) | Common Stock | 804 | USD 82.64 | USD 66,443 | SEC 申报 ↗ |
| 2026-08-12 | Yu Jonathan Yen-Wen | 期权行权／转换 (M) | Common Stock | 804 | USD 13.50 | USD 10,854 | SEC 申报 ↗ |
| 2026-08-06 | Khara Rahul | 卖出 (S) | Common Stock | 5,000 | USD 80.00 | USD 400,000 | SEC 申报 ↗ |
| 2026-08-06 | Khara Rahul | 期权行权／转换 (M) | Common Stock | 5,000 | USD 14.69 | USD 73,450 | SEC 申报 ↗ |
| 2026-07-13 | Quisel John D | 卖出 (S) | Common Stock | 33,000 | USD 74.96 | USD 2,473,791 | SEC 申报 ↗ |
| 2026-07-13 | Quisel John D | 期权行权／转换 (M) | Common Stock | 33,000 | USD 10.68 | USD 352,374 | SEC 申报 ↗ |
| 2026-07-07 | Yu Jonathan Yen-Wen | 卖出 (S) | Common Stock | 100 | USD 82.50 | USD 8,250 | SEC 申报 ↗ |
| 2026-07-07 | Yu Jonathan Yen-Wen | 期权行权／转换 (M) | Common Stock | 100 | USD 13.50 | USD 1,350 | SEC 申报 ↗ |
| 2026-06-29 | Khara Rahul | 卖出 (S) | Common Stock | 1,649 | USD 75.00 | USD 123,675 | SEC 申报 ↗ |
| 2026-06-29 | Khara Rahul | 期权行权／转换 (M) | Common Stock | 1,649 | USD 14.69 | USD 24,224 | SEC 申报 ↗ |
| 2026-06-26 | Yu Jonathan Yen-Wen | 卖出 (S) | Common Stock | 300 | USD 72.50 | USD 21,750 | SEC 申报 ↗ |
| 2026-06-26 | Yu Jonathan Yen-Wen | 期权行权／转换 (M) | Common Stock | 300 | USD 13.50 | USD 4,050 | SEC 申报 ↗ |
| 2026-06-26 | Khara Rahul | 卖出 (S) | Common Stock | 851 | USD 75.00 | USD 63,825 | SEC 申报 ↗ |
| 2026-06-26 | Khara Rahul | 期权行权／转换 (M) | Common Stock | 851 | USD 14.69 | USD 12,501 | SEC 申报 ↗ |
| 2026-06-22 | Yu Jonathan Yen-Wen | 卖出 (S) | Common Stock | 9,700 | USD 72.66 | USD 704,802 | SEC 申报 ↗ |
| 2026-06-22 | Yu Jonathan Yen-Wen | 期权行权／转换 (M) | Common Stock | 9,700 | USD 13.50 | USD 130,950 | SEC 申报 ↗ |
| 2026-06-18 | Quisel John D | 卖出 (S) | Common Stock | 34,000 | USD 70.22 | USD 2,387,328 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | IRON |
| CIK | 0001816736 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 482 transaction lines from 2020-08-14 to 2026-09-15 21 P purchase lines · 350 S sale lines · 111 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.